After evaluating the company's pipeline ahead of the Q4 results later this month, JPMorgan analyst Chris Schott says shares of Mylan are setup for outperformance. The company's pipeline opportunities "substantially de-risk" near- to intermediate-term outlook while Mylan's 2018 earnings per share guidance for greater than $5.40 is "highly achievable" assuming a mid-year generic Advair approval, Schott tells investors in a research note. The analyst views the shares as "highly inexpensive" at current levels and keeps an Overweight rating on the name with a $53 price target.